Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.
The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.
Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.
Burkitt’s Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase II Study of CPI-613 for Patients with Recurrent or Persistent Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with High-Risk Genetic Changes
Ariela Noy
[Protocol 18-443]
A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
Chronic Lymphocytic Lymphoma (CLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Venetoclax and Obinutuzumab as Initial Therapy for Chronic Lymphocytic Leukemia
Anthony Mato
[Protocol 20-044]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]
A Phase I/II Study of LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Anthony Mato
[Protocol 19-077]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase II Study of Ublituximab and Umbralisib in Combination with Ibrutinib or Venetoclax to Treat Chronic Lymphocytic Leukemia
Anthony Mato
[Protocol 19-225]
Diffuse Large B-Cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase III Study of Acalabrutinib plus R-CHOP Therapy in Patients 65 and Younger with Previously Untreated Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 21-141]
A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase III Study of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin in People with Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 20-031]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]
A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]
Follicular Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase II Study of ME-401 in People with Recurrent or Persistent Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 19-246]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase IB/III Study of Lenalidomide and Rituximab plus Tazemetostat or Placebo in Patients with Recurrent or Persistent Follicular Lymphoma
Connie Lee Batlevi
[Protocol 20-252]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]
A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 21-164]
HIV+ Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Ariela Noy
[Protocol 17-543]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
Hodgkin Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 16-1536]
Prior Treatment (Relapsed/Refractory)
A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 17-073]
A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 17-054]
A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 18-160]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
A Phase II Study of Tislelizumab Immunotherapy in People with Recurrent or Persistent Classical Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 21-082]
Mantle Cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]
A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
A Phase I Study of Glofitamab Alone or in Combination with Obinutuzumab in People with Recurrent or Persistent Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 20-569]
Marginal Zone Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease d
A Phase III Study of Ibrutinib with Rituximab in People with Untreated Marginal Zone Lymphoma
Ariela Noy
[Protocol 19-243]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase II Study of ME-401 in People with Recurrent or Persistent Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 19-246]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
Mediastinal Grey Zone Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
Small Lymphocytic Lymphoma (SLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]
A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
Andrew D. Zelenetz
[Protocol 16-1614]
A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
T-cell Lymphoma: PTCL, CTCL and Extranodal NK nasal type
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042] PTCL only
A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Niloufer Khan
[Protocol 18-147] CTCL only
A Phase I Study of TTI-621 Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347] CTCL only
PTCL only
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210] CTCL only
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297] PTCL only
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535] Both
Waldenstrom’s Macroglobulinemia
Newly Diagnosed/Frontline Studies and Advanced Disease
Prior Treatment (Relapsed/Refractory)
A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]
A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]
A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]
A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]
A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 19-297]
A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 20-240]
A Phase II Study of Nanatinostat and Valganciclovir in People with Epstein-Barr Virus-Associated Lymphoma
Erel Joffe
[Protocol 20-535]
